First Quantum Minerals Reports First Quarter 2024 Results
GlobeNewswire
(In United States dollars, except where noted otherwise)
TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- First Quantum..
South African Health Products Regulatory Authority
News and Video Search Results
News coverage
-
South Africa: Sahpra Recalls Two Batches of Benylin Paediatric Cough Syrup
allAfrica.com
-
GITEX Africa Morocco returns in 2024 with strong line-up of tech topics, set to fast-track continent’s future digital economy
EQS Group
-
Nigeria: 2023 Year Of Cash Crunch And Naira Swap – Analysis
Eurasia Review
-
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire
0 shares
1 views
You might like
South African Health Products Regulatory Authority media coverage
WHO, UN, FDA, CDC are part of a complex to deceive the world, says Peter McCullough, MD
Rumble
“The W.H.O. appears to be… [part of a] biopharmaceutical complex.” “[This complex] includes the W.H.O. (World Health..
-
Middle East Veterinary Vaccine Market Expected to Grow at 4% CAGR, Reaching US$ 973.8 Billion by 2033 | Future Market Insights Inc.
GlobeNewswire
-
South Africa Professional Bodies Activity Report 2023 with Profiles of 100+ Associations
GlobeNewswire
-
Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
GlobeNewswire
-
Veru Reports Fiscal 2023 Third Quarter Financial Results
GlobeNewswire
Advertisement
More coverage
Silentium Tech receives regulatory approval from SAHPRA to bring new tinnitus treatment, Cleanhearing Sono, to South Africa.
Pressat
Friday 3 February, 2023Silentium Tech has received approval from the South African Health Products Regulatory Authority (SAHPRA) to..
-
Global Nutraceuticals Market is projected to be valued at USD 650 Billion growing at a CAGR of 8.13% during 2022-2027: Bonafide Research
GlobeNewswire
-
Bavarian Nordic A/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue
GlobeNewswire
-
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
GlobeNewswire
-
Giyani Announces the Results of its Feasibility Study for the K.Hill Battery-Grade Manganese Project
GlobeNewswire